Anita Mahajan on the Nurse's Role When Treating Patients with Brain Cancer

Throughout April, the FDA approved drugs for the treatment of diseases including solid tumors, lung cancer, multiple myeloma, bladder cancer, and low-grade glioma.

Jacki Garcia, RN, BSN, CNRN; and Kristin Hendrickson, BA, RN, discuss phase 0 trials and how they can help expedite the research process for brain cancer therapies.

The FDA approved tovorafenib for certain patients with relapsed or refractory pediatric low-grade glioma.

Eflornithine (Iwilfin) received FDA approval to reduce the risk for relapse in pediatric and adult patients with high-risk neuroblastoma, making it the first therapy to reduce risk for relapse in children with the disease.

A brain tumor diagnosis can be daunting. Nurses are on the front lines connecting patients to available resources and walking them through the best treatment options.

Vorasidenib reduced the risk of progression or death by 61% compared with placebo for patients with grade 2 IDH-mutant glioma.